Case Study: Bisphosphonate-Linked Osteonecrosis in Diabetes

This article originally appeared here.
Share this content:
Case Study: Bisphosphonate-Linked Osteonecrosis in Diabetes
Case Study: Bisphosphonate-Linked Osteonecrosis in Diabetes

MONDAY, Nov. 2, 2015 (HealthDay News) -- A case of bisphosphonate-related osteonecrosis of the jaw is described in an elderly patient with diabetes mellitus. The report is published in the October issue of the Journal of the American Geriatrics Society.

Lizette Valenzuela, M.D., from the Hospital Universitario de Getafe in Madrid, and colleagues describe the case of an 80-year-old woman who presented to the emergency department with a two-week history of progressive dyspnea, dysphagia, and odynophagia. The patient had latent autoimmune diabetes mellitus, with poor glycemic control and complicated with microvascular disease. She had osteoporosis and had been receiving intravenous bisphosphonates since 20 months earlier.

According to the report, physical examination on admission revealed a ballooning in the floor of the mouth and trismus. A pronounced protrusion toward the posterior border of the tongue was seen on laryngeal fibroscopy and a large abscess was seen on the floor of the mouth on computed tomography of the neck. The patient underwent urgent surgery for abscess drainage. Suspicion of a tooth infection was suggested as a possible source of the abscess. An exposed bone in her mandible was detected, despite treatment by her dentist for longer than three months. Any systemic or local malignancy was excluded. Diabetes mellitus was the only risk factor noted for bisphosphonate-related osteonecrosis of the jaw.

"Prevention is the best option and should be done before starting treatment with a bone-modifying agent," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths